The Duodenal Ulcer Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Duodenal Ulcer Treatment Market:
https://www.thebusinessresearchcompany.com/report/duodenal-ulcer-treatment-global-market-report
According to The Business Research Company’s Duodenal Ulcer Treatment Global Market Report 2024, The duodenal ulcer treatment market size has grown strongly in recent years. It will grow from $93.42 billion in 2023 to $99.99 billion in 2024 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to increased patient preference for non-invasive treatments, growth in gastrointestinal health awareness, increase in the number of cigarette smokers, increase in the number of alcohol or tobacco consumers, and increase in the integration of digital health solutions.
The duodenal ulcer treatment market size is expected to see strong growth in the next few years. It will grow to $133.10 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to the increasing number of diseases, an increasing number of medical infrastructure and healthcare facilities, growing awareness about the availability of treatment options, growing preference for minimally invasive procedures, and increasing efforts to spread awareness by the government. Major trends in the forecast period include technological advancements, integration of probiotics, telemedicine, nutritional therapy, and evidence-based practice integration.
The increase in the number of cigarette smokers is expected to propel the growth of the duodenal ulcer treatment market going forward. A cigarette smoker is an individual who habitually consumes cigarettes, which are small, tobacco-filled paper rolls that are smoked by inhaling and exhaling the resulting smoke. The increase in cigarette smoking is due to cultural influences, public policies, and socioeconomic conditions. Treating duodenal ulcers in cigarette smokers involves a comprehensive approach that includes ulcer-specific treatments, smoking cessation interventions, lifestyle modifications, and regular monitoring to optimize healing and reduce the risk of recurrence. For instance, in September 2023, according to the Office for National Statistics, a UK-based government department, in the UK, around 6.4 million adults over 18 smoked cigarettes in 2022, accounting for 12.9% of the population. Additionally, the age group of 16 to 24 years old was the one with the greatest rate of e-cigarette use in 2022, 15.5% of persons in this age group reported vaping regularly, up from 11.1% in 2021. Therefore, an increase in the number of cigarette smokers is driving the growth of the duodenal ulcer treatment market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=18339&type=smp
The duodenal ulcer treatment market covered in this report is segmented –
1) By Type: Antibiotics, Proton Pump Inhibitors, Antacids, Potassium-Competitive Acid Blockers, H2-Antagonist, Ulcer Protective Drugs, Surgery
2) By Application: Adult, Elderly
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Major companies operating in the duodenal ulcer treatment market are focusing on developing innovative products, such as combikit for duodenal ulcers and H pylori infection, to enhance the healing of duodenal ulcers. A combi kit for duodenal ulcer and H. pylori infection typically refers to a combination therapy approach that includes medications to heal the ulcer and eradicate the H. pylori bacteria. For instance, in April 2023, Akums Drugs and Pharmaceutical Limited, an India-based pharmaceutical company, launched an innovative Combikit to treat duodenal ulcers associated with Helicobacter pylori (H. pylori) infection. The unique features of Combikit integrate three potent medications, amoxicillin, clarithromycin, and esomeprazole, which effectively inhibit the growth of H. pylori bacteria and reduce gastric acid production, addressing the primary causes of duodenal ulcers. The Central Drugs Standard Control Organization (CDSCO) has approved this Combikit to treat duodenal ulcers and eradicate H. pylori in patients with active or healed peptic ulcers.
The duodenal ulcer treatment market report table of contents includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
